

Tuberculosis profile: Cambodia

Population 2019: 16 million

Estimates of TB burden*, 2019

	Number	(Rate per 100 000 population)
Total TB incidence	47 000 (31 000-68 000)	287 (186-410)
HIV-positive TB incidence	1 300 (810-1 800)	7.6 (4.9-11)
MDR/RR-TB incidence**	1 000 (500-1 700)	6.1 (3-10)
HIV-negative TB mortality	2 900 (1 800-4 200)	17 (11-25)
HIV-positive TB mortality	410 (260-590)	2.5 (1.6-3.6)

Estimated proportion of TB cases with MDR/RR-TB*, 2019

New cases	1.8% (1.2-2.8)
Previously treated cases	8.2% (4-16)

Universal health coverage and social protection*


TB treatment coverage (notified/estimated incidence), 2019	63% (44-98)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	7% (4-11)

TB case notifications, 2019

Total new and relapse	29 906
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	95%
- % pulmonary	64%
- % bacteriologically confirmed ^	54%
- % children aged 0-14 years	6%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)



HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2019

(Number)

- % women	42%
- % men	52%
Total cases notified	30 017

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	750	2.7%
- on antiretroviral therapy	725	97%

Drug-resistant TB care, 2019


% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	
Laboratory-confirmed cases - MDR/RR-TB ^^	135
Patients started on treatment - MDR/RR-TB ^^	135
Laboratory-confirmed cases - XDR-TB ^^	0
Patients started on treatment - XDR-TB ^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	

Treatment success rate and cohort size


	Success	Cohort
New and relapse cases registered in 2018	94%	28 611
Previously treated cases, excluding relapse, registered in 2018	88%	137
HIV-positive TB cases registered in 2018		
MDR/RR-TB cases started on second-line treatment in 2017	70%	135
XDR-TB cases started on second-line treatment in 2017	100%	1

TB preventive treatment, 2019


% of HIV-positive people (newly enrolled in care) on preventive treatment	
---	--



Treatment success rate



Total budget



% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	45% (42-50)
---	----------------

TB financing

National TB budget, 2020 (US\$ millions)	33
- Funding source, domestic	19%
- Funding source, international	32%
- unfunded	49%

* Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

^ Calculated for pulmonary cases only

^^ Includes cases with unknown previous TB treatment history

^^^ Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed

Generated 2020-10-15 by the World Health Organization (<https://www.who.int/tb/data/>)